SUZANNE FUQUA to Mutation
This is a "connection" page, showing publications SUZANNE FUQUA has written about Mutation.
Connection Strength
1.820
-
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022 02; 126(2):174-186.
Score: 0.278
-
ESR1 mutations in breast cancer. Cancer. 2019 11 01; 125(21):3714-3728.
Score: 0.238
-
A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions. Breast Cancer Res Treat. 2010 Jul; 122(2):381-93.
Score: 0.121
-
Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice. Oncogene. 2009 Sep 10; 28(36):3177-87.
Score: 0.119
-
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat. 2010 Jan; 119(1):71-85.
Score: 0.116
-
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43.
Score: 0.103
-
Evidence that CRISPR-Cas9 Y537S-mutant expressing breast cancer cells activate Yes-associated protein 1 to driving the conversion of normal fibroblasts into cancer-associated fibroblasts. Cell Commun Signal. 2024 Nov 14; 22(1):545.
Score: 0.086
-
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer. 2021 01; 124(1):191-206.
Score: 0.065
-
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 01; 60(15):4026-9.
Score: 0.064
-
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer. Horm Cancer. 2018 08; 9(4):215-228.
Score: 0.055
-
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997 Apr 01; 57(7):1244-9.
Score: 0.051
-
ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg". JAMA Oncol. 2016 10 01; 2(10):1315-1316.
Score: 0.049
-
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016 06; 157(2):253-265.
Score: 0.048
-
ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action. Clin Cancer Res. 2016 Mar 01; 22(5):1034-6.
Score: 0.046
-
Estrogen receptor (ER) a mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat. 2014 Feb; 144(1):11-9.
Score: 0.041
-
Estrogen receptor mutations in breast cancer. J Cell Biochem. 1993 Feb; 51(2):135-9.
Score: 0.038
-
Expression of estrogen receptor variants. J Cell Biochem Suppl. 1993; 17G:194-7.
Score: 0.038
-
Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):243-7.
Score: 0.037
-
Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010 May 15; 16(10):2702-8.
Score: 0.031
-
Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol. 2006 Sep; 20(9):2020-35.
Score: 0.024
-
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275.
Score: 0.020
-
Estrogen receptor and breast cancer. Semin Cancer Biol. 2001 Oct; 11(5):339-52.
Score: 0.017
-
The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2001 Oct; 6(4):407-17.
Score: 0.017
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
Score: 0.016
-
Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines. Cancer Lett. 2018 08 01; 428:12-20.
Score: 0.014
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.013
-
The p53 tumor-suppressor gene in human breast cancer. Cancer Treat Res. 1994; 71:63-77.
Score: 0.010
-
The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202.
Score: 0.009
-
William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat. 1993; 27(1-2):95-102.
Score: 0.009
-
Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep. 2013; 3:2256.
Score: 0.009
-
Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15; 52(2):483-6.
Score: 0.009
-
The importance of normal and abnormal oestrogen receptor in breast cancer. Cancer Surv. 1992; 14:31-40.
Score: 0.009
-
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene. 2010 Apr 22; 29(16):2404-14.
Score: 0.008
-
BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol. 2010 Jan; 24(1):76-90.
Score: 0.008
-
Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993; 26(3):225-35.
Score: 0.002